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INTRODUCTION
Pseudoxanthoma elasticum (PXE), an autosomal 
recessive genodermatosis, is characterized by ectopic 
deposition of calcium hydroxyapatite in the skin, eyes, and 
the cardiovascular system, with considerable morbidity 
and occasional early mortality (For review see [1, 2]). 
The majority of cases with the classic form of PXE result 
from biallelic inactivating mutations in the ABCC6 gene. 
ABCC6 mutations can also cause generalized arterial 
calcification of infancy (GACI), another autosomal 
recessive disorder characterized by severe ectopic 
mineralization of the cardiovascular system that begins 
during fetal development [3, 4]. ABCC6 encodes a 
transmembrane efflux transporter, ABCC6, expressed 
primarily in the liver, to a lesser extent in the kidneys, and 
at very low levels, if at all, in tissues subject to ectopic 
mineralization [5, 6]. These observations, together with 
results from animal studies, have suggested that PXE 
is a metabolic disorder deficient in circulating factor(s) 
required physiologically to prevent ectopic mineralization 
[7, 8]. While the precise physiologic function of ABCC6 
is currently unclear, recent studies have indicated that 
ABCC6 is required for release of ATP from hepatocytes 
to the extracellular milieu where it is readily converted 
enzymatically to inorganic pyrophosphate (PPi) and AMP 
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ABSTRACT
Pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy 
(GACI) are heritable disorders manifesting with ectopic tissue mineralization. Most 
cases of PXE and some cases of GACI are caused by mutations in the ABCC6 gene, 
resulting in reduced plasma pyrophosphate (PPi) levels. There is no effective treatment 
for these disorders. It has been suggested that administration of bisphosphonates, 
stable and non-hydrolyzable PPi analogs, could counteract ectopic mineralization 
in these disorders.  In this study we tested the potential efficacy of etidronate, a 
first generation bisphosphonate, on ectopic mineralization in the muzzle skin of 
Abcc6-/- mice, a model of PXE. The Abcc6-/- mice received subcutaneous injections of 
etidronate, 0.283 and 3.40 mg/kg per injection (0.01× and 0.12×), twice a week, in 
both prevention and reversal studies. Ectopic mineralization in the dermal sheath of 
vibrissae in muzzle skin was determined by histopathologic analysis and by direct 
chemical assay for calcium content. Subcutaneous injection of etidronate prevented 
ectopic mineralization but did not reverse existing mineralization. The effect of 
etidronate was accompanied by alterations in the trabecular bone microarchitecture, 
determined by micro-computed tomography. The results suggest that etidronate may 
offer a potential treatment modality for PXE and GACI caused by ABCC6 mutations. 
Etidronate therapy should be initiated in PXE patients as soon as the diagnosis is 
made, with careful monitoring of potential side effects. 
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by ectonucleotide pyrophosphatase/phosphodiesterase 1 
(ENPP1), an enzyme encoded by ENPP1 [9, 10]. Since 
PPi is physiologically a powerful anti-mineralization 
factor and proper PPi/Pi ratio in circulation is required to 
prevent ectopic mineralization, loss-of-function mutations 
in ABCC6 result in a reduced extracellular concentration 
of ATP and lowered PPi/Pi ratio, which then allow ectopic 
mineralization to ensue in patients with PXE. 
There is currently no effective or specific treatment 
for PXE. The observations of reduced plasma PPi levels in 
PXE have led to the suggestion that administration of PPi 
would encounter ectopic mineralization, but unfortunately, 
PPi is unstable with relatively short half-life in circulation 
[11]. Recent studies have suggested, however, that 
administration of stable PPi analogs, bisphosphonates, 
could be used for treatment of ectopic mineralization 
disorders [12]. Bisphosphonates are structural analogs of 
PPi in which the oxygen linkage between phosphonate 
(PO3) groups is replaced by a carbon. Bisphosphonates 
also have two side groups (R1, R2), and different 
substitutions at these side chains alter their pharmacologic 
characteristics, specificity and relative potency [13, 14]. 
Bisphosphonates have two principal modes of action on 
mineral metabolism: (a) They can display physicochemical 
anti-mineralization properties that inhibit through 
their ability to limit the growth of mineral crystals, 
and (b) they exhibit biochemical properties that enable 
them to inhibit osteoclast activity. The latter property 
is the premise of their use in treatment of conditions 
characterized by bone loss, particularly osteoporosis [15]. 
Different bisphosphonates have various degrees of anti-
mineralization and anti-osteoclastic activities. The first 
generation bisphosphonates, such as etidronate (ETD), 
a non-nitrogen containing bisphosphonate, displays 
considerable anti-mineralization activity, but is a relatively 
low-potency inhibitor of osteoclasts. By contrast, the 
third generation, nitrogen-containing bisphosphonates, as 
exemplified by alendronate (AST), are significantly more 
potent inhibitors of osteoclasts than the non-nitrogen 
containing ones, but the low doses required for this 
effect preclude administration of these drugs in quantities 
sufficient to exert significant inhibition of mineralization. 
We recently initiated studies to explore the potential 
of bisphosphonates for treatment of ectopic mineralization 
disorders by administration of ETD or AST to genetically 
engineered mutant mice depicting extensive cutaneous 
and vascular mineral deposits. In one set of studies, these 
bisphosphonates were administered orally or by subcutaneous 
injections to Enpp1asj mice, a model for GACI, a severe 
disorder in which the patients often die within the first year 
of life from complications of vascular calcification [16]. The 
results suggested that these two bisphosphonates, particularly 
ETD, were capable of preventing ectopic mineralization in 
the dermal sheath of vibrissae and in the aorta. Furthermore, 
preliminary studies using a mouse model for PXE, 
the Abcc6tm1JfK mice (referred hereon as Abcc6-/- mice), 
demonstrated that feeding of ETD reduced mineralization 
at the early stages of the process [17]. However, relatively 
high doses of ETD were needed, probably due to the fact 
that absorption of ETD from the gastrointestinal track is 
poor, typically 1% or less [14]. Furthermore, these studies 
did not address the question of whether bisphosphonates are 
capable of reversing the ectopic mineralization by enhancing 
resorption of pre-existing calcium hydroxyapatite. 
The Abcc6-/- mice have been shown to have 
markedly reduced PPi/Pi plasma ratio due to decreased PPi 
levels but normal Pi and calcium serum concentrations. 
[9, and Li et al., unpublished]. In this study, we have 
tested the efficacy of ETD in both preventing the ectopic 
mineralization process and in potentially reversing the 
existing calcification by subcutaneous injection of ETD 
into Abcc6 knockout mice. 
RESULTS
Experimental design
The Abcc6-/- mouse recapitulates features of PXE 
by developing late onset (5–6 weeks of age) and slowly 
progressing mineralization of the dermal sheath of 
vibrissae in the skin, Bruch’s membrane in the eye, and 
in the arterial blood vessels of the cardiovascular system 
[18]. The first site of mineralization is the dermal sheath 
of vibrissae, a connective tissue capsule surrounding 
the sinus adjacent to the hair bulb of vibrissae. We have 
previously shown that the mineralization of this dermal 
sheath is progressive and reflects the mineralization of 
arterial blood vessels, thus allowing us to monitor the 
temporal degree of mineralization in this mouse model 
by histopathology or direct chemical assay of calcium 
in biopsies of muzzle skin or by non-invasive micro-
computed tomography (µCT) [19, 20].
In this study, two sets of experimental design 
were utilized to test the efficacy of ETD. In the first set 
of experiments (Set 1), the Prevention Study, Abcc6-/- 
mice were treated with ETD by subcutaneous injections 
twice per week, initiated at weaning at 4 weeks of age, 
i.e., before mineralization develops, and continued for 
another 8 weeks. This experiment allowed us to determine 
whether ETD can prevent ectopic mineral deposition in 
these mice. The second set of experiments (Set 2), the 
Reversal Study, allowed the mice to grow up to 12 weeks 
of age, i.e., the age at which clearly detectable ectopic 
mineralization is present. The mice were then subjected 
to ETD administration by subcutaneous injections for 
another 12 weeks. In both sets of experiments, two doses 
of ETD were used, 0.283 and 3.40 mg per kg of body 
weight per injection; these concentrations correspond to 1 
percent (0.01×) and 12 percent (0.12×) of the typical oral 
dose used for treatment of osteoporosis in adult human 
patients (8 mg/kg/day assuming 50 kg body weight; http://
www.rxlist.com/didronel-drug.htm). For proper amount of 
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ETD to be injected, the mice were weighed every week, 
and the dose was adjusted accordingly per g body weight. 
In both experiments, mice were treated in parallel with 
saline injections. Each group consisted of 7–10 mice, 
with approximately equal distribution between males and 
females (Table 1).
At the end of each experiment, the mice were 
sacrificed, and the degree of mineralization in the dermal 
sheath of vibrissae was determined semi-quantitatively 
by staining tissue sections with Alizarin red or by direct 
chemical assay of calcium content in the biopsies of 
muzzle skin containing the dermal sheath of vibrissae. 
Since ETD is known to affect the morphology of long 
bones, the femurs of these mice were examined separately 
in male and female mice by µCT. 
Etidronate prevents ectopic mineralization in the 
skin
In the first set of experiments, ETD or saline 
injections were initiated at 4 weeks of age, a time point 
at which no ectopic mineralization is as yet present. At 
12 weeks of age, Abcc6-/- mice that had been injected 
with saline revealed extensive ectopic mineralization in 
the dermal sheath of vibrissae (Figure 1). Injection of 
either 0.01× ETD or 0.12× ETD significantly reduced the 
degree of mineralization as determined semi-quantitatively 
by histopathologic examination (Figure 1) or by direct 
quantitative assay of calcium content of the muzzle 
skin (Figure 2). Wild type mice on the corresponding 
strain background (C57BL/6J) did not develop ectopic 
mineralization in the vibrissae (not shown).
Etidronate does not reverse the existing ectopic 
mineralization in Abcc6-/- mice
Examination of the dermal sheath of vibrissae of 
the Abcc6-/- mice that were untreated controls or were 
injected with saline at 24 weeks of life demonstrated 
progressive mineralization as compared to mice at 12 
weeks of age (Figures 1 and 2). Injection of ETD, 0.01× or 
0.12× between 12 and 24 weeks of age, resulted in lower 
level of mineralization than in mice injected with saline. 
However, the degree of mineralization, as quantitated by 
chemical assay of calcium content, in ETD treated mice 
at 24 weeks of age was of the same order of magnitude 
as in those injected with saline at 12 weeks of age. These 
results indicate that ETD administration did not resolve 
the mineral deposits that had accumulated in the mice 
before the treatment was started at 12 weeks of age as 
shown in Set 1. Rather, further mineralization in Set 2 was 
arrested at the level that existed at 12 weeks of age but did 
not lower the value below the baseline (Figure 2). 
Etidronate modifies the bone microarchitecture
Because ETD possesses both anti-mineralization 
and anti-osteoclastic activities, we further evaluated the 
morphometric microarchitecture of the trabecular bone 
in the ETD treated mice by µCT analysis of their femurs. 
Marked differences in the bone density and trabecular 
microarchitecture were noted between the male and female 
mice, consistent with previous reports [16, 17, 21, 22]. 
Consequently, sex-matched comparisons of the µCT 
results were performed between Abcc6-/- mice and 
Table 1: Experimental groups of Abcc6-/- mice by genotype and treatment*
Group, injected with Genotype No. of mice examined (M+F)
Treatment started > 
treatment ended (weeks)
Prevention Study (Set 1):
saline Abcc6-/- 7 (3+4) 4 > 12
0.01× ETD Abcc6-/- 10 (5+5) 4 > 12
0.12× ETD Abcc6-/- 10 (6+4) 4 > 12
NT Abcc6-/- 10 (5+5) 4 > 12
Reversal Study (Set 2):
saline Abcc6-/- 10 (5+5) 12 > 24
0.01× ETD Abcc6-/- 10 (5+5) 12 > 24
0.12× ETD Abcc6-/- 10 (5+5) 12 > 24
NT Abcc6-/- 10 (5+5) 12 > 24
NT Abcc6+/+ 10 (5+5) 12 > 24
*All the mice were placed on control diet at 4 weeks of age post-weaning. In Prevention Study, the mice at 4 weeks of 
age were injected subcutaneously with saline, 0.01× ETD or 0.12× ETD, for an additional 8 weeks. Mineralization was 
determined at 12 weeks of age. In Reversal Study, the Abcc6-/- mice were allowed to develop mineralization up to 12 weeks 
of age and they were then injected and followed for an additional 12 weeks. At this point, at 24 weeks of age, the mice were 
euthanized for analysis. ETD, etidronate; M, male; F, female; NT, not treated.
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Figure 1: Histopathology with Alizarin red stain demonstrates that etidronate treatment prevents, but does not reverse, 
ectopic soft tissue mineralization in Abcc6-/- mice. The Abcc6-/- mice develop ectopic mineralization of the dermal sheath of vibrissae 
prior to 12 weeks of age, and this process progresses to 24 weeks of age. Subcutaneous injection of etidronate at 0.01× and 0.12× doses 
during 4–12 weeks markedly reduced the degree of mineralization in the dermal sheath of vibrissae, when compared to age-matched Abcc6-/- 
mice receiving saline injections (left 3 panels). Etidronate treatment from 12 to 24 weeks of age prevented further mineralization but did not 
reverse mineralization that had developed prior to 12 weeks of age (right 3 panels). ETD, etidronate; KO, knockout. Scale bar = 400 µm.
Figure 2: Etidronate treatment prevents vibrissae mineralization as determined by the direct chemical assay of 
calcium. Note the significantly elevated calcium content in the muzzle skin of  Abcc6-/- mice, either NT or injected with saline, as 
compared with the WT mice (right panel). Injections of Abcc6-/- mice subcutaneously with 0.01× and 0.12× ETD significantly reduced the 
calcium content of the muzzle skin as compared with age-matched mice injected with saline. Etidronate treated Abcc6-/- mice at 24 weeks 
of age demonstrated mineralization similar to Abcc6-/- mice at 12 weeks of age, indicating that ETD prevents further mineralization but 
does not reverse mineralization that had developed before initiation of treatment. *p < 0.05, **p < 0.01, compared to KO mice at 12 weeks 
of age; ++p < 0.01, compared to KO mice at 24 weeks of age. Mean ± SE; n = 7–10 mice per group. ETD, etidronate; KO, knockout; WT, 
wild type; NT, not treated. 
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the corresponding wild type mice on the same strain 
background as well as with mice treated with 0.01× or 
0.12× ETD in both sets of experiments. No significant 
differences in the bone microarchitecture between the 
Abcc6-/- mice and the corresponding, sex-matched wild type 
mice were noted (Table 2). However, treatment of the mice 
with ETD resulted in marked increase in the bone mass 
(Figure 3). These changes of bone microarchitecture were 
quantified using manufacturer-provided software (Table 2). 
In treated mice, the distal femoral bone volume fraction 
(BV/TV, %) was increased, corresponding to the increased 
trabecular bone mineral density (BMD). ETD treatment 
also caused increased trabecular number (Tb.N), decreased 
trabecular separation (Tb.Sp), decreased structure model 
index (SMI) and connectivity density (Conn.D). These 
results attest to the potency of ETD in anti-osteoclastic 
activities directed at bone.
DISCUSSION
PXE, a prototype of heritable ectopic mineralization 
disorders, manifests with progressive deposition of 
calcium hydroxyapatite crystals in soft connective 
tissues, particularly in the skin and the cardiovascular 
system. The disease is of late-onset, and the average age 
at diagnosis is in early teens, although in some patients 
the diagnosis is not reached until in their late thirties or 
forties [1, 2]. GACI is clinically overlapping, yet more 
severe, ectopic mineralization disorder, the majority of 
patients dying from cardiovascular complications during 
their first year of life [23, 24]. Another, recently described 
ectopic mineralization disorder is arterial calcification 
due to CD73 deficiency (ACDC) which manifests with 
late-onset of mineralization affecting primarily the arterial 
blood vessels in the lower extremities and the periarticular 
ligaments and tendons [25]. The genetic basis of these 
three conditions resides within a pathway involved in 
generation of PPi and Pi, the mutations in classic PXE 
being in ABCC6, in GACI in ENPP1, and in ACDC in 
NT5E (Figure 4) [1, 26]. Thus, the unifying pathogenetic 
feature of these conditions is reduced plasma PPi/Pi ratio 
which allows ectopic mineralization in peripheral tissues 
to ensue [1, 9, 23, 25]. 
A number of spontaneous and genetically engineered 
mutant mice have been characterized with ectopic 
mineralization of soft connective tissues in the skin and 
vascular connective tissues, and many of them recapitulate 
features of PXE, GACI and ACDC, respectively [26, 27]. 
In a particular, the Abcc6-/- mouse serves as an appropriate 
model for PXE, characterized by late-onset mineralization 
of skin, eyes, and the arterial blood vessels [18, 28]. 
Examination of these mice by energy dispersive X-ray 
and Fourier transform infrared imaging spectroscopy 
(FT-IRIS) indicated that the principal components of the 
mineral deposits in tissues are calcium and phosphate, 
and the Ca/P ratio increases in samples with progressive 
mineralization reaching a value of close to 2:1, comparable 
to that in endochondral bone [29]. Progressively increasing 
mineralization is also reflected by increased mineral-to-
matrix ratio, and the determination of the mineralization 
process by FT-IRIS suggested progressive maturation of 
the mineral deposits from amorphous calcium phosphate 
to hydroxyapatite [29]. In this study, we utilized Abcc6-/- 
mice as a model for PXE to test the potential efficacy of 
ETD, a stable PPi analog. Bisphosphonates, such as ETD, 
can prevent ectopic mineralization by incorporation into 
calcium hydroxyapatite mineral crystals preventing their 
growth [30]. 
There is no specific or effective treatment for PXE, 
and previous clinical trials attempting to counteract the 
mineralization process, such as increasing the magnesium 
content of the diet or feeding phosphate binders, have 
Figure 3: Etidronate treatment of Abcc6-/- mice results in altered femur microarchitecture. Note the distinct difference 
between male (upper panel) and female (lower panel) mice, assessed by µCT scan. Treatment with etidronate caused changes in femur 
microarchitecture, as quantitatively detailed in Table 2. Three males and 3 females were examined in each group with similar findings. 
ETD, etidronate; KO, knockout; WT, wild type; NT, not treated.
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Table 2: Trabecular bone phenotypes by microCT of the right distal femur of the mice*
Group, 
injected with Sex
BMD  
(mg/cm3)
BV/TV 
(%)
Tb.Th 
(µm)
Tb.N  
(1/mm)
Tb.Sp (µm) SMI Conn.D  
(TV/mm3)
Prevention Study (Set 1):
KO, saline M 988.1 ± 8.2 8.9 ± 1.1 33.6 ± 1.9 4.7 ± 0.1 207.5 ± 7.2 2.3 ± 0.2 222.6 ± 34.7
KO, saline F 963.4 ± 5.2 5.2 ± 0.4 29.7 ± 0.2 4.0 ± 0.1 246.4 ± 3.0 2.7 ± 0.1 124.0 ± 30.4
KO, 0.01× ETD M 1064.5 ± 30.9+ 9.8 ± 1.3 34.1 ± 0.6 5.3 ± 0.1+ 212.1 ± 18.0 2.1 ± 0.1 250.7 ± 46.5
KO, 0.01× ETD F 999.5 ± 7.1+ 10.2 ± 1.2+ 33.3 ± 1.5 4.9 ± 0.3+ 197.3 ± 12.3+ 2.0 ± 0.2+ 282.5 ± 37.9+
KO, 0.12× ETD M 1023.4 ± 1.8+ 18.0 ± 1.5++ 36.5 ± 0.7 6.0 ± 0.2++ 156.6 ± 6.9++ 1.1 ± 0.2+ 402.0 ± 28.0+
KO, 0.12× ETD F 1146.6 ± 67.0+ 15.1 ± 1.6++ 34.4 ± 1.2+ 5.5 ± 0.5+ 177.5 ± 16.2+ 1.4 ± 0.2++ 400.6 ± 73.9+
Reversal Study (Set 2):
KO, saline M 993.1 ± 7.5 8.7 ± 1.2 35.2 ± 2.5 4.3 ± 0.1 224.9 ± 3.8 2.1 ± 0.2 169.5 ± 13.8
KO, saline F 981.0 ± 2.6 3.4 ± 0.3 33.7 ± 1.1 2.9 ± 0.1 345.2 ± 10.0 2.9 ± 0.1 53.6 ± 8.5
KO, NT M 994.4 ± 9.2 12.8 ± 3.4 41.6 ± 5.0 4.4 ± 0.2 219.0 ± 13.0 1.7 ± 0.3 166.1 ± 8.4
KO, NT F 988.0 ± 11.2 4.2 ± 0.5 32.7 ± 1.2 3.2 ± 0.1 316.7 ± 12.5 2.5 ± 0.1 81.1 ± 8.4
KO, 0.12× ETD M 1033.2 ± 10.5+ 20.4 ± 2.7 44.6 ± 1.1 5.2 ± 0.3 184.1 ± 13.3 0.8 ± 0.2 220.4 ± 16.3+
KO, 0.12× ETD F 982.1 ± 11.3 12.5 ± 1.2++ 38.9 ± 1.4+ 3.9 ± 0.1++ 250.3 ± 6.1++ 1.3 ± 0.1++ 167.5 ± 11.5++
WT, NT M 1003.8 ± 10.2 13.6 ± 0.1 48.2 ± 1.0 4.2 ± 0.2 226.2 ± 8.8 1.7 ± 0.2 140.2 ± 11.8
WT, NT F 1003.3 ± 1.6 3.8 ± 0.8 34.8 ± 0.4 3.0 ± 0.2 335.0 ± 19.8 2.8 ± 0.1 59.5 ± 17.9
*For a description of different groups, see Table 1. Values are expressed as mean ± SE (three mice of each sex per group). 
Statistical significance in comparison to age-matched untreated KO mice of the same sex is indicated: +p < 0.05, ++p < 0.01. 
BMD, bone mineral density (mg/cm3); BV/TV, relative bone volume (%); Tb.Th, trabecular thickness (µm); Tb.N, trabecular 
number (1/mm); Tb.Sp, trabecular separation (marrow thickness, µm); SMI, structure model index; Conn.D, connectivity 
density (TV/mm3). ETD, etidronate; M, male; F, female; NT, not treated.
Figure 4: The PPi and Pi generating pathway points to the critical role of components of the pro-mineralization/anti-
mineralization network. Mutations in the ABCC6, ENPP1, and NT5E genes cause pseudoxanthoma elasticum (PXE), generalized 
arterial calcification of infancy (GACI), and arterial calcification due to CD73 deficiency (ACDC), respectively. ABCC6, a putative 
transmembrane transporter, mediates ATP release from hepatocytes to extracellular space where ATP is converted to PPi and AMP by 
ENPP1, a membrane-bound pyrophosphatase/phosphodiesterase. CD73 converts AMP to Pi and adenosine, the latter one being an inhibitor 
of tissue nonspecific alkaline phosphatase (TNAP), an extracellular, yet membrane-bound protein, that hydrolyze PPi to Pi. PPi is an anti-
mineralization factor, and Pi is a pro-mineralization factor. Deficiencies in ABCC6, ENPP1 and CD73 proteins lead to reduced plasma PPi 
levels and PPi/Pi ratio, thereby promoting mineralization in peripheral tissues. EC, extracellular; IC, intracellular.
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highlighted the challenges of the trials in these patients 
with slowly progressing and unpredictable clinical 
progression [31, 32]. Such clinical trials are further 
complicated by considerable phenotypic, both intra- and 
inter-familial, variability which may be compounded 
by modifying genetic factors and life style variables, 
such as diet and exercise [33]. In this study, we have 
specifically tested the potential of ETD as a treatment of 
PXE under carefully controlled laboratory conditions on a 
genetically defined mouse strain background. Our results 
demonstrated that ETD, at the dosages used was able to 
prevent ectopic mineralization in mice when started before 
the onset of the mineralization process, as demonstrated by 
our Prevention Study. However, once the mineral deposits 
had accumulated in soft connective tissue, ETD did not 
reverse the extent of mineralization but arrested further 
deposition of mineral at the point when the treatment was 
initiated. These observations would imply that if ETD is 
to be used to treat patients with PXE, it is ideally started as 
soon as the diagnosis has been established. In this regard, 
a pre-symptomatic mutation analysis can establish the 
diagnosis of PXE in asymptomatic patients in families 
with previous history of PXE [34]. Therefore, one would 
recommend that all siblings, particularly younger ones, 
of patients diagnosed with PXE should be examined for 
ABCC6 mutations to establish their genotypic status.
Because ETD has previously shown to be effective 
for treatment of disorders characterized by loss of bone 
mass, such as osteoporosis and osteogenesis imperfecta 
but also bone destruction by cancer metastases [15, 35], 
we determined the morphometric characteristics of bones 
in PXE mice with and without treatment with ETD. 
The results demonstrated that untreated PXE mice, at 
least up to 24 weeks of age, did not show differences in 
bone morphology as compared with wild type control 
mice of the same genetic strain background. Whether 
such findings are applicable to PXE patients as well 
remains to be determined by bone scanning analyses in 
patients. Treatment of Abcc6-/- mice with ETD resulted in 
significant increases in bone mass, as determined by µCT. 
These results indicated that ETD in dosages used in our 
study was effective in modifying the bone density, and 
they also suggested that ETD could potentially have dual 
beneficial effects in patients with PXE both by preventing 
ectopic mineralization and increasing bone mass as part of 
prevention of osteoporosis. 
Recently (May, 2015), a clinical trial for treatment 
of ectopic mineralization in PXE was registered in the 
Netherland’s Trial Registry (NTR5180; http://www.
trialregister.nl/trialreg/admin/rctview.asp?TC=5180). 
This randomized, double-blinded and placebo controlled 
study proposes to test the efficacy of ETD (20 mg/kg 
per day) cycling for 2 weeks on and 10 weeks off for 12 
months compared with placebo. The primary end point 
is the degree of mineralization in the leg arteries after 
12 months of treatment as measured by 18F-NaF uptake. 
Secondary objectives include the effects of ETD therapy 
on calcium scores of the peripheral arteries, attenuation of 
ongoing calcification in other arteries than leg arteries, and 
ophthalmological and dermatological changes. Based on our 
preclinical mouse studies reported here, one would predict 
that ETD in this clinical study will attenuate the progression 
of mineralization but does not reverse the existing level of 
mineralization with accompanied clinical manifestations. 
This prediction is based on the assumption that the efficacy, 
pharmacokinetics, and metabolism of ETD are similar in 
mice and humans. Indeed, it will be interesting to see whether 
ETD treatment in this clinical trial will show beneficial 
effects to patients with PXE. These clinical trials should also 
consider the established risks associated with bisphosphonate 
treatment, such as bone pain or tenderness, osteonecrosis 
and bone fractures [36]. Prolonged continued treatment 
has also been reported to cause nephrotic syndrome. In 
addition to PXE, a study on a case series of patients with 
GACI suggested that bisphosphonate treatment of newborns 
with this disease was associated with the survival beyond 
infancy, although the precise mechanism of this effect 
was not established [12]. Finally, a clinical trial proposes 
to treat patients with ACDC with ETD (NCT01585402; 
https://clinicaltrials.gov/show/NCT01585402) and is 
currently recruiting participants. Thus, all these conditions 
of ectopic mineralization presenting with reduced PPi/
Pi ratio may be candidates for bisphosphonate treatments, 
particularly ETD, to counteract the clinical manifestations. 
Finally, it should be noted that other approaches to increase 
the PPi/Pi ratio in patients with ectopic mineralization 
disorders should be considered, including increased 
release of ATP to the extracellular milieau, enhancement of 
ENPP1 activity [37], and inhibition of tissue non-specific 
alkaline phosphatase (TNAP) [38] (see Figure 4), towards 
development of molecularly designed pharmacologic agents 
with anti-mineralization potential.
MATERIALS AND METHODS
Mice
The Abcc6tm1JfK mouse was developed by targeted 
ablation of the Abcc6 gene (this mouse is referred to as 
Abcc6-/-) [18]. The Abcc6 null allele was backcrossed for ten 
generations into the C57BL/6J strain to create a congenic 
strain (B6.Cg). Abcc6 wild type (Abcc6+/+) and knockout 
(Abcc6-/-) mice were generated from heterozygous breeding. 
Mice were fed a standard rodent diet (Lab Diet 5010; PMI 
Nutrition, Brentwood, MO, USA) with free access to water. 
Mice were maintained in the Animal Facility of Thomas 
Jefferson University in a temperature- and humidity-
controlled environment. All protocols were approved 
by the Institutional Animal Care and Use Committee of 
Thomas Jefferson University. Proper handling and care 
were practiced according to the animal welfare policies of 
the United States Public Health Service.
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Experimental design and treatment
WT and Abcc6-/- mice were placed on the standard 
rodent diet throughout the experiment. Mice were injected 
with saline or etidronate (ETD) subcutaneously, twice a 
week. Mice were divided into four groups: (i) mice were 
not treated; mice were injected with (ii) sterile saline, 
(iii) 0.01× ETD, or (iv) 0.12× ETD. The 1× dose was 
calculated to be equivalent to that used for the treatment 
of humans for osteoporosis (8 mg/kg/day orally).  The 
dose of 0.01× ETD was based on the assumption of 1% of 
intestinal absorption of ETD, whereas 100% absorption by 
subcutaneous injection [13, 14, 39]. Mice were assigned 
into the Prevention Study (Set 1) and the Reversal Study 
(Set 2) groups with appropriate controls. The groups 
of mice in the two sets, characterized by genotype and 
treatment, are described in Table 1. In Set 1, Abcc6-/- mice 
were injected with ETD beginning at 4 weeks of age for 
a total of 8 weeks, 7–10 mice per group. All mice were 
euthanized at 12 weeks of age for tissue analysis. In Set 
2, Abcc6-/- mice were injected with ETD beginning at 
12 weeks of age for a total of 12 weeks, 10 mice per group, 
and were euthanized at 24 weeks of age for tissue analysis.
Histopathological analysis
Biopsies from muzzle skin containing vibrissae 
were fixed in 10% phosphate-buffered formalin and 
embedded in paraffin. Paraffin sections (6 µm thick) were 
stained with Hematoxylin and Eosin and Alizarin red 
using standard methods. Slides were examined under light 
microscopy for mineralization.
Chemical quantitation of calcium in the muzzle 
skin
To quantify calcium deposition in vibrissae, muzzle 
skin biopsies were decalcified with 0.15 mol/L HCl 
for 2 days at room temperature. Solubilized calcium 
was then determined by a colorimetric assay using the 
ơ-cresolphthalein complexone method [calcium (CPC) 
LiquiColor; Stanbio Laboratory, Boerne, TX]. The amount 
of calcium was normalized to tissue weight. 
Micro-computed tomography
Microarchitecture of the distal trabecular bone 
of the right femur was determined in a 1.25 mm-thick 
region located proximal to the distal growth plate of 
femur by scanning at a 10.5 µm resolution using the 
micro-computed tomography (µCT) system (vivaCT40; 
Scanco Medical AG, Bassersdorf, Switzerland). The 
microstructural parameters were obtained through 
3-dimensional reconstruction using a Gaussian filter 
and a global threshold of 2272 Hounsfield units in the 
manufacturer-provided software.
Statistical analysis
We performed comparisons between different groups 
of mice using the 2-sided Kruskal–Wallis nonparametric 
test. Statistical significance was reached with p < 0.05. 
All statistical computations were completed using SPSS 
version 15.0 software (SPSS Inc., Chicago, IL).
Abbreviations
PXE, pseudoxanthoma elasticum; GACI, 
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